Surufatinib + Anti-PD-1/L1
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small Cell Lung Cancer
Conditions
Extensive-Stage Small Cell Lung Cancer
Trial Timeline
Sep 27, 2022 → Jul 31, 2024
NCT ID
NCT05509699About Surufatinib + Anti-PD-1/L1
Surufatinib + Anti-PD-1/L1 is a phase 2 stage product being developed by HUTCHMED for Extensive-Stage Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05509699. Target conditions include Extensive-Stage Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05509699 | Phase 2 | Completed |
Competing Products
20 competing products in Extensive-Stage Small Cell Lung Cancer